Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Thyroid function during the first year of use of the injectable contraceptive depot medroxyprogesterone acetate

Texto completo
Autor(es):
Quintino-Moro, Alessandra [1] ; Zantut-Wittmann, Denise Engelbrecht [2] ; Silva dos Santos, Priscilla de Nazare [1] ; Melhado-Kimura, Vaneska [1] ; da Silva, Conceicao Aparecida [2] ; Bahamondes, Luis [1] ; Fernandes, Arlete [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Med Sch UNICAMP, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Med Sch UNICAMP, Dept Internal Med, Div Endocrinol, Campinas, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. 24, n. 2, p. 102-108, MAR 4 2019.
Citações Web of Science: 0
Resumo

Purpose: The aim of the study was to evaluate thyroid function profile as a possible factor influencing weight and body composition variation in new users of depot medroxyprogesterone acetate (DMPA).Materials and methods: A prospective, non-randomised, comparative study was conducted at the University of Campinas, Brazil. Women aged 18-40years with a body mass index (BMI) less than 30kg/m(2), normal oral glucose tolerance test, no known diseases, and using no medication, who opted to use DMPA were paired by age (1year) and BMI (1kg/m(2)) with women initiating copper intrauterine device (IUD) use. The main outcome measures were thyroid function profile, weight, and body composition, as measured by dual-energy X-ray absorptiometry. We used repeated measures ANOVA to perform comparisons between times and groups.Results: We evaluated 28 DMPA users and 24 IUD users who completed the 12-month follow-up. We observed that FT4 levels were higher at 12months (compared to baseline) in the DMPA group (p<.0001) and that FT4/FT3 ratio had increased in both groups. Additionally, at 12months, total body mass had increased around 2kg and lean mass increased in the DMPA group compared to the IUD group; there was also an increase in weight, BMI, total body mass, and fat mass when compared to baseline.Conclusions: No changes in thyroid function occurred that could explain the weight increase observed in DMPA users. (AU)

Processo FAPESP: 09/53293-0 - Estudo prospectivo de avaliação da resistência insulínica, metabolismo de lípedes e repercussão subclínica de doença cardiovascular em mulheres que iniciam o uso do contraceptivo injetável trimestal de acetato de medroxiprogesterona de depósito em segmento de 2 anos
Beneficiário:Luis Guillermo Bahamondes
Modalidade de apoio: Auxílio à Pesquisa - Pesquisa em Políticas Públicas para o SUS